It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
We assess the relationships between retinal and choroidal structural and microvascular parameters and brain volumetric magnetic resonance imaging (MRI) parameters in individuals with amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD).
Methods
Participants underwent optical coherence tomography (OCT) and OCT angiography (OCTA) imaging using the Zeiss Cirrus HD-5000 AngioPlex (Carl Zeiss Meditec, Dublin, CA) and volumetric brain MRI imaging with NeuroQuant (CorTechs Labs, San Diego, CA) analysis. Retinal and choroidal structural and microvascular parameters were extracted from OCT and OCTA scans. Superficial capillary plexus perfusion density and vessel density in the 3 × 3 mm and 6 × 6 mm circles and rings centered on the fovea were determined. Hippocampal, superior lateral ventricle (SLV), and inferior lateral ventricle (ILV) volumes were determined. Correlations between OCT, OCTA, and volumetric MRI parameters in patients with aMCI and AD were explored using Spearman partial correlation analysis.
Results
68 eyes of 37 aMCI participants and 64 eyes of 33 AD participants were analyzed. In the eyes with aMCI, hippocampal volume negatively correlated with FAZ area and positively correlated with perfusion density and vessel density in the 3 mm OCTA scan. In the aMCI cohort, SLV and ILV volume inversely correlated with perfusion density in the 3 mm and 6 mm OCTA scans, respectively. In the eyes with AD, SLV and ILV volume inversely correlated with perfusion density and vessel density in the 3 mm and 6 mm OCTA scans. Central subfield thickness, ganglion cell-inner plexiform layer thickness, RNFL thickness, and choroidal vascularity index did not significantly correlate with SLV, ILV, or hippocampal volume in any cohorts (p > 0.05).
Conclusions
Decline in retinal microvascular parameters significantly correlated with hippocampal volume loss and ventricular expansion, suggesting that these parameters may mirror cerebral neurodegeneration in individuals with aMCI and AD.
Trial registration
Clinical trial identifier: NCT03233646, registration date: July 20, 2017.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer